Very recently, a phase 1 open-label study tested ivosidenib or enasidenib in combination with induction chemotherapy in patients with either IDH1- or IDH2-mutated newly diagnosed AML [98]. This evidence concerns the gene IDH1 and acute myeloid leukemia.